Search Results for “mental health” – Page 19 – media

New eye medicine company will lay tens of billions of “golden eggs”

In front of the old domestic eye medicine leaders such as Yisheng Bio and Xingqi Eye Medicine, Zhaoke Ophthalmology is a young upstart. In 2021, Zhaoke Ophthalmology successfully landed on the Hong Kong Stock Exchange as the second eye medicine biotechnology company with 25 ophthalmic drug candidates. Three years later, although it has not yet gotten out of the quagmire of losses, Zhaoke Ophthalmology is still working hard in the eye medicine track and finally ushered in the opportunity to overtake on the curve. Two years of rapid growth, fierce attack on the “first billion drug” Recently, Zhaoke Ophthalmology announced that the Phase III clinical trial (China CHAMP) of its eye medicine candidate NVK002 has achieved positive top-line results. NVK002 is an experimental new topical ocular solution for controlling the deepening of myopia in children and adolescents (using 0.01% and 0.02% low-dose atropine). This is the most popular atropine myopia ...
- Source: drugdu
- 68
- November 9, 2024
Analytica Vietnam

Organiser：Messe München GmbH (Munich Exhibition Center) Time：April 2nd – 4th, 2025 Address：Plot No. 23 – 25 & 27 – 29, Knowledge Park – II, Gautam Budh Nagar, Greater NOIDA – 201306 Exhibition hall：Saigon Exhibition and Convention Center (SECC) Product range: Medical Products: Medical equipment and instruments, medical consumables, medical dressings, surgical equipment, emergency rescue equipment, diagnostic equipment and supplies, ophthalmic instruments and equipment, ENT equipment, dental equipment and supplies, medical reagents and equipment, medical healthcare products and equipment, medical institution and laboratory technology equipment, medical information and technology exchange, beauty instruments. Analytical Instruments: Optical analytical instruments, mass spectrometers, spectroscopes, chromatographs, spectrographs, spectrometers, electrochemical analytical instruments, ray analytical instruments, gas chromatographs, liquid chromatographs, thermal analytical instruments, various portable instruments, surface analytical instruments, nuclear analytical instruments, elemental analytical instruments, process analytical instruments, compositional analytical instruments, injection analytical instruments, and other general analytical instruments. Laboratory Equipment: Laboratory instruments and equipment, laboratory automation ...
- Source: drugdu
- 65
- November 7, 2024
$1.4 billion deal highlights the future of Alzheimer’s disease therapy

The development of therapies for Alzheimer’s disease has always caused many developers to feel exhausted, and now AbbVie has also increased its investment in neurodegenerative diseases. AbbVie has agreed to spend $1.4 billion to acquire Aliada Therapeutics, whose main acquisition asset is Aliada’s authorized Alzheimer’s disease candidate drug ALIA-1758 from Johnson&Johnson. Its mechanism of action is still an anti beta amyloid protein (3pE-A β) antibody, but the unique feature of ALIA-1758 is that it can cross the blood-brain barrier, greatly improving the brain’s absorption rate. Aliada started a phase 1 trial among healthy volunteers in May, but AbbVie believes the timing is ripe for acquisition. Previously, AbbVie made the decision to abandon its internal Alzheimer’s disease asset ABBV-916. This anti beta amyloid antibody has no significant difference in safety and efficacy compared to the already marketed monoclonal antibody therapy for Alzheimer’s disease. Therefore, AbbVie decided to terminate the development ...
- Source: drugdu
- 57
- November 5, 2024
Nat Commun | Professor Ouyang Songying’s team reveals the activation mechanism of Sir2 HerA system in pathogenic bacteria’s phage immunity

In the long-term and intense survival competition between bacteria, archaea, and bacteriophages, they have evolved various complex antiviral systems to resist the invasion of bacteriophages. The latest research reveals that approximately 7% of sequenced bacterial genomes have at least one defense system, among which the depletion of nicotinamide adenine dinucleotide (NAD+) is a common strategy to combat phage induced miscarriage infections. The hydrolysis of NAD+is mainly performed by proteins containing TIR and Sir2 domains. Recently, Professor Ouyang Songying’s team from the School of Life Sciences at Fujian Normal University collaborated to publish a paper titled “Mechanical Basis for the Allosteric Activation of NADase Activity in the Sir2 HerA Antiphage Defense System” online in Nature Communications. This study uses bioinformatics, structural biology, and experimental techniques such as biochemistry to reveal the molecular mechanism of how the Sir2 HerA system is activated and exerts its anti phage function in pathogen immunity.The Sir2 ...
- Source: drugdu
- 55
- November 4, 2024
The 3rd Analysis and Testing Summit Forum and Academic Annual Conference of the Journal of Analysis and Testing in 2024 grandly opened in Guangzhou

From September 21st to 25th, 2024, the “2024 Analysis and Testing Summit Forum and Annual Conference of Analysis and Testing Academic Newspaper” jointly organized by the Journal of Analysis and Testing, the Testing and Analysis Research Institute of Guangdong Academy of Sciences (Guangzhou Analysis and Testing Center, China), the China Association for Analysis and Testing, and the Guangdong Association for Analysis and Testing was held at the Nikko Hotel in Guangzhou. This forum focuses on innovation and development in the field of analysis and testing, attracting more than 1000 academicians, scholars, and business representatives from various cutting-edge fields such as environment and health, life analysis, food safety, new technologies, and scientific instrument development; By adopting a combination of online and offline modes, we have successfully attracted over 10000 online viewers, breaking down geographical boundaries and expanding our audience base. On the morning of the 23rd, the forum was officially opened. ...
- Source: drugdu
- 76
- November 1, 2024
The second day of the 2024 National Negotiations | Hengrui, CSPC Pharmaceutical, Qilu Pharmaceutical, AstraZeneca…appeared! Antidiabetic and tumor drugs may be the focus

The 2024 National Medical Insurance Negotiations entered the second day. Beijing was sunny. On this day, antidiabetic and tumor drugs were the highlights. On the second day of the National Negotiations, Huang Bin, Vice President of AstraZeneca China, and Xia Yu, founder, chairman, president and CEO of Kangfang Bio, appeared at the National Negotiations. On the morning of October 28, the companies participating in the negotiations included AstraZeneca, Hengrui, Xinlitai, Hisun, CSPC Pharmaceutical, etc.; in the afternoon, Zhejiang Jingxin Pharmaceutical, Union Qilin, Beijing Novartis, Luye Pharmaceutical, Jiangsu Hausen, Bristol-Myers Squibb, Qilu, Changchun Jinsai, Zejing Bio, Hengrui, Novo Nordisk, etc. were present. Some on-site observers said that anti-tumor, antidiabetic and other chronic disease drugs were the protagonists of the second day of the National Negotiations. The National Medical Insurance Administration has carried out adjustments to the medical insurance drug list for six consecutive years, adding a total of 744 drugs to ...
- Source: drugdu
- 57
- October 30, 2024
Continuously Advancing Digital Marketing for Attenuated Live Vaccines Against Shingles

On October 28, Baike Biology (688276) held a performance briefing for the third quarter of 2024. The company’s board members, including General Manager Kong Wei, Executive Deputy General Manager Jiang Chunlai, and Board Secretary Zhang Zhe, communicated with investors regarding the operating results and financial status for the third quarter of 2024. Baike Biology is an innovative biopharmaceutical company mainly focused on infectious disease prevention and control. Since its establishment, it has primarily engaged in the research, development, production, and sale of human vaccines. The company currently has approved vaccines, including chickenpox vaccines, intranasal flu vaccines, and shingles vaccines. Among these, the chickenpox vaccine has maintained a leading market share for many years, making it one of the company’s primary sources of revenue. The intranasal flu vaccine is a part of the World Health Organization’s (WHO) Global Influenza Action Plan (GAP) and is the only attenuated live influenza vaccine administered ...
- Source: drugdu
- 68
- October 30, 2024
Are stem cells the “terminator” of diabetes? Chinese scientists used stem cell regeneration therapy to cure type 1 diabetes for the first time

Cell, an international authoritative scientific journal, recently published a pioneering achievement from multiple research teams in China – the first time to use stem cell regeneration therapy to functionally cure type 1 diabetes. The research team used chemical reprogramming technology to induce pluripotent stem cells to prepare islet cells, and transplanted them to a type 1 diabetes patient, achieving clinical functional cure effect. So, how is it successful to induce stem cells to prepare pancreatic islet cells? Is functional cure truly a cure? Will stem cell technology be the key to conquer diabetes in the future? What is the difference between functional cure and cure Diabetes is a thorny disease, and its biggest harm to patients is that there are many clinical complications, which may lead to cardiovascular disease, nervous system damage, kidney disease, eye disease, foot disease, and so on. Diabetes ranks ninth among the world’s ten leading ...
- Source: drugdu
- 94
- October 28, 2024
Hengrui Medicine Reports Revenue and Net Profit Growth in Q3

On the evening of October 24, Hengrui Medicine announced its Q3 performance report for 2024, showcasing steady growth in performance. For the first three quarters of 2024, Hengrui reported an operating revenue of 20.189 billion yuan, marking an increase of 18.67% year-on-year. The net profit attributable to shareholders reached 4.620 billion yuan, an increase of 32.98%, while the net profit after deducting non-recurring gains and losses was 4.616 billion yuan, reflecting a 37.38% increase, demonstrating robust development momentum. According to the report, Hengrui’s R&D expenditures reached 4.549 billion yuan in the first three quarters of 2024, marking a significant increase of 22% year-on-year. This ongoing high-intensity investment in R&D is providing strong momentum for the transformation of the company’s innovative achievements. As a result of these sustained investments, Hengrui is seeing a continual emergence of innovative outcomes. During the reporting period, Hengrui launched its self-developed Class 1 new drug, Fuhuanqi ...
- Source: drugdu
- 84
- October 28, 2024
A strong alliance! Bluesail Medical joins hands with Wanhua Chemical to welcome major opportunities and benefits

In the fields of medicine, scientific research, manufacturing, etc., professional-grade disposable consumables often play a pivotal role. These seemingly simple but crucial products not only bear the heavy responsibility of ensuring safety and improving efficiency, but also require the deep integration of cutting-edge technological innovation and practical applications, which also makes the research and development of high-end disposable consumables a complex and sophisticated system engineering. However, technological innovation does not exist in isolation. It must be rooted in actual needs and requires strong alliances between powerful companies. Now, this practice has another typical example of cooperation. Recently, Bluesail Medical and Wanhua Chemical signed a strategic cooperation agreement at Wanhua Chemical’s Cishan headquarters and held a joint innovation laboratory unveiling ceremony. The content of this cooperation is mainly for both parties to give full play to their strengths and carry out deep integration, namely “Wanhua Chemical’s polyurethane industry chain advantages and ...
- Source: drugdu
- 94
- October 25, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.